Tegoprazan prevents NSAID ulcers as well as lansoprazole

Theme

Tegoprazan 25 mg Active comparator: lansoprazole 15 mg 24-week prevention trial

Tegoprazan vs lansoprazole for preventing NSAID-related peptic ulcers

Source
Source: PubMed-style record for Kim SG et al., a phase III randomized, double-blind, active-controlled multicenter study of tegoprazan versus lansoprazole for prevention of NSAID-induced peptic ulcer. The record lists ClinicalTrials.gov identifier NCT04840550 and publication in Gut Liver, online ahead of print, 2026.

Tegoprazan matched lansoprazole for preventing NSAID-related peptic ulcers over 24 weeks, with comparable safety.

Why it matters

Long-term NSAID use raises the risk of gastroduodenal peptic ulcers, so gastroprotection is often needed when anti-inflammatory therapy must continue.

Study at a glance
Design
Phase III, randomized, double-blind, active-controlled, multicenter
Population
Patients continuing NSAID therapy
Arms
Tegoprazan 25 mg vs lansoprazole 15 mg
Follow-up
Up to 24 weeks
Central finding
Tegoprazan arm
25 mg Investigational gastroprotective regimen
Primary endpoint met
Non-inferior Peptic ulcer incidence at week 24
p=0.0004 Non-inferiority analysis
Comparator arm
15 mg Active comparator: lansoprazole
Trial size
392 patients randomized
269 included in the per-protocol analysis
Efficacy
Met NI tegoprazan was non-inferior to lansoprazole for ulcer prevention at week 24
p=0.0004 primary endpoint
Symptoms & safety
Week 12 heartburn-free rate favored tegoprazan
No sig. difference adverse drug reactions and serious adverse events
Endpoint evidence board
Domain Endpoint / timepoint Reported quantitative result Interpretation
Efficacy Peptic ulcer incidence
Primary endpoint, week 24		 Non-inferiority met
p=0.0004
 Tegoprazan matched lansoprazole for prevention of NSAID-induced gastroduodenal ulcers over 24 weeks.
Symptoms Heartburn-free rate
Week 12		 Favored tegoprazan
Exact percentage not provided in the supplied brief.
 Symptom signal favored tegoprazan at week 12.
Safety Adverse drug reactions Comparable
No significant between-group difference reported.
 Overall tolerability was similar between tegoprazan and lansoprazole.
Safety Serious adverse events Comparable
No significant between-group difference reported.
 No meaningful safety separation was reported between treatment groups.
Numbers to know
392 randomized patients
269 per-protocol analysis set
24 weeks of ulcer-prevention follow-up
25 mg vs 15 mg tegoprazan vs lansoprazole dose comparison

For patients who require continuous long-term NSAID therapy, tegoprazan 25 mg appears to be an effective and well-tolerated alternative to lansoprazole 15 mg for peptic ulcer prevention.

AbbreviationsQuick
Abbreviations: NSAIDs, nonsteroidal anti-inflammatory drugs; ADRs, adverse drug reactions; SAEs, serious adverse events.
Bibliography1
  1. Kim SG, Kim TO, Jung SW, Min BH, Oh JH, Kim HS, et al. A Phase III, Randomized, Double-Blind, Active-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Tegoprazan for the Prevention of Peptic Ulcer in Patients on Continuous Long-Term Treatment with Nonsteroidal Anti-Inflammatory Drugs. Gut Liver. 2026 Jun 22. Online ahead of print. PMID: 42325011. (DOI: 10.5009/gnl260057)
👀 View Mode